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maximum plasma concentration and area under the plasma 
concentration curve (AUC) for lapatinib, as well as the AUC 
of paclitaxel, were increased when combined. The most 
common adverse events (AEs) related to the study treatment 
were alopecia, diarrhea and decreased hemoglobin. The 
majority of drug-related AEs were Grade 1 or 2. The median 
overall survival was 35.6 months (95 % confidence interval 
23.9, not reached). The response rate and clinical benefit rate 
were both 83 % (95 % confidence interval 51.6, 97.9).
Conclusions The L+P treatment was well tolerated in 
Japanese patients with HER2-positive MBC. Although 
the PK profiles of lapatinib and paclitaxel influenced each 
other, the magnitudes were not greatly different from those 
in non-Japanese patients.
Keywords Lapatinib · Paclitaxel · HER2 · Metastatic 
breast cancer
Abstract 
Background Lapatinib is the human epidermal growth fac-
tor receptor 2 (HER2) targeting agent approved globally for 
HER2-positive metastatic breast cancer (MBC). The efficacy, 
safety and pharmacokinetics (PK) of lapatinib combined with 
paclitaxel (L+P) were investigated in this study, to establish 
clear evidence regarding the combination in Japanese patients.
Methods In this two-part, single-arm, open-label study, 
the tolerability of L+P as first-line treatment in Japanese 
patients with HER2-positive MBC was evaluated in six 
patients in the first part, and the safety, efficacy and PK 
were evaluated in a further six patients (making a total of 
twelve patients) in the second part. Eligible women were 
enrolled and received lapatinib 1500 mg once daily and 
paclitaxel 80 mg/m2 weekly for at least 6 cycles.
Results The only dose-limiting toxicity reported was 
Grade 3 diarrhea in one patient. The systemic exposure to 
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Introduction
Overexpression or gene amplification of human epidermal 
growth factor receptor 2 (HER2) occurs in approximately 
20 % of breast cancer cases. It is known to be an independ-
ent prognostic factor that shortens survival of patients, and 
is associated with high rates of cell proliferation and lymph 
node metastases [1, 2]. At present, the standard regimens 
used worldwide are the trastuzumab-containing regimens, 
which have significantly improved the prognosis for HER2-
positive breast cancer [3, 4]. One of the key combination 
regimens containing trastuzumab is with taxane and is rec-
ommended by clinical practice guidelines globally [3–5]. 
However, the majority of patients experience tumor recur-
rences and/or metastases and, hence, further treatment 
options for primary care as well as in the metastatic setting 
are required. Another important issue is the occurrence of 
brain metastases due to the inability of trastuzumab to cross 
the intact blood–brain barrier. Cardiotoxicity has been recog-
nized as one of the important side-effects [6–11]. Lapatinib 
tosylate hydrate is a small molecule that reversibly inhibits 
the activity of epidermal growth factor receptor (EGFR) and 
HER2 tyrosine kinases. Lapatinib was first approved in the 
USA in 2006 in combination with capecitabine for HER2-
positive metastatic breast cancer (MBC) which persisted 
or recurred after anthracycline, taxane and trastuzumab 
treatment. The approved condition is the same worldwide, 
including in Japan. Lapatinib has been evaluated in other 
combinations, such as trastuzumab, aromatase inhibitor and 
paclitaxel. Its combination with paclitaxel is approved in 
some countries/regions as first-line treatment for HER2-pos-
itive MBC patients in whom trastuzumab is not appropriate.
Lapatinib is a small molecule that passes through the 
compromised blood–brain barrier and is suggested to exert 
anti-tumor activity in metastatic brain lesions [12, 13]. This 
characteristic approach of lapatinib led to the development 
of lapatinib in combination with paclitaxel as first-line ther-
apy of HER2-positive MBC, as a replacement for the tras-
tuzumab regimens.
The first Phase I study of a lapatinib and paclitaxel 
combination (L+P) in HER2-positive MBC patients was 
conducted outside Japan. This study demonstrated the tol-
erability of lapatinib (1500 mg/day) in combination with 
both weekly paclitaxel 80 mg/m2 and with tri-weekly 
paclitaxel 135, 175, 200 and 225 mg/m2 [14]. Follow-
ing this, the combination of lapatinib (1500 mg/day) and 
tri-weekly paclitaxel (175 mg/m2) as first-line therapy 
was evaluated in a Phase III study, in which 579 HER2-
negative or unknown, advanced or recurrent breast cancer 
patients were enrolled [15]. Of 579 patients enrolled, 83 
had HER2-positive MBC, and the combination regimen 
showed significant improvement in progression-free sur-
vival (PFS) compared to paclitaxel monotherapy [hazard 
ratio (HR) = 0.49; 95 % confidence interval (CI) 0.3–0.8; 
p = 0.008]. In another Phase III study that was mainly con-
ducted in China and South America, the combination of 
lapatinib (1500 mg/day) with weekly paclitaxel (80 mg/
m2) as first-line therapy was evaluated in 444 patients with 
HER2-positive MBC [16]. The overall survival (OS) of the 
combination was prolonged compared to paclitaxel mono-
therapy (HR = 0.74; 95 % CI 0.58–0.94; p = 0.0124). The 
combinations of lapatinib (1250 mg/day) or trastuzumab 
either with paclitaxel or docetaxel as first-line therapy for 
HER2-positive MBC were evaluated in a global Phase III 
study including Japan, which was conducted mainly in the 
USA/EU [17]. The study enrolled 636 patients; the results, 
reported in 2012, showed that the PFS of the lapatinib com-
bination was not significantly different compared with the 
trastuzumab regimen [HR = 1.33 (95 % CI 1.06–1.67); 
p = 0.01].
In order to extrapolate the data from the above studies 
conducted outside Japan to clinical practice in Japan, we 
have conducted this study to investigate the tolerability, 
safety and pharmacokinetics (PK) of a lapatinib 1500 mg 
and weekly paclitaxel combination.
Patients and methods
Patients
Eligible patients were Japanese women older than 18 years 
with histologically confirmed invasive HER2-positive 
MBC, which was defined as immunohistochemistry (IHC) 
3+ or fluorescence in situ hybridization (FISH)-positive 
(an amplification ratio ≥2.2) evaluated by a local labora-
tory. Patients were required to have at least one measur-
able lesion according to the Response Evaluation Criteria 
in Solid Tumors (RECIST) version 1.0 [18]. Patients must 
have received no prior therapy for metastatic diseases. 
Additional inclusion criteria were: Eastern Cooperative 
Oncology Group performance status of 0 or 1; left ven-
tricular ejection fraction (LVEF) within the institutional 
normal range (or ≥50 %, if unavailable); adequate renal, 
hepatic and hematologic functions.
Major exclusion criteria were: prior therapy with an 
EGFR and/or HER2 inhibitor other than trastuzumab; unre-
solved/unstable, serious toxicity from prior therapy with 
investigational drug and/or anticancer treatment; uncon-
trolled infection; ≥Grade 2 peripheral neuropathy accord-
ing to National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI-CTCAE) version 3.0; 
malabsorption syndrome or other conditions that would 
prevent the efficacy and safety evaluation of the study regi-
men. All patients provided written informed consent. The 
study was conducted in accordance with good clinical 
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practice and all applicable regulatory requirements, includ-
ing the Declaration of Helsinki.
Study design
This was a single-arm, two-part, open-label Phase I/II study 
(ClinicalTrials.gov Identifier: NCT01138046). The objec-
tives were to evaluate the tolerability, safety, efficacy and 
PK of L+P in Japanese patients with HER2-positive MBC 
who have not received prior chemotherapy or trastuzumab 
for metastatic diseases. Six patients were enrolled in the 
first part (Part 1) to evaluate the tolerability of this regimen, 
and once the tolerability was confirmed, a further 6 patients 
were enrolled in the second part (Part 2). Sample size was 
not decided by statistical considerations.
Patients were given the standard treatment consisting 
of 6 cycles of weekly paclitaxel 80 mg/m2 (for 3 weeks in 
a 4-week cycle) combined with lapatinib 1500 mg daily; 
the latter was given until disease progression or withdrawal 
from study treatment due to unacceptable toxicity or con-
sent withdrawal. The investigators could chose to continue 
concurrent paclitaxel administration for more cycles. For 
patients enrolled in Part 1, lapatinib was not given on day 1, 
but started on the following day, and paclitaxel was not given 
on day 15, but was given within 2 days after that date during 
the first cycle for PK evaluation purposes. If disease progres-
sion, unacceptable paclitaxel-related toxicities, or termina-
tion of lapatinib occurred, then paclitaxel was terminated at 
any time during the study, even before completing 6 cycles.
Study endpoints
The objective in Part 1 was tolerability. If one or no patient 
out of the 6 experienced any events included in the toler-
ability criteria, the study treatment was concluded to be tol-
erable. PK parameters were also evaluated.
The efficacy and safety of the treatment in twelve patients 
were the objectives of Part 2. The study was not designed 
based on statistical hypotheses, as the study targeted a small 
population and was designed as single-arm stud;, however, 
in order to compare with the OS of the previous study, our 
efficacy evaluation was primarily focused on OS. The other 
endpoints of efficacy were PFS, time to response, duration 
of response, objective tumor response rate (ORR) and clini-
cal benefit rate [complete response (CR) or partial response 
(PR) or stable disease (SD) ≥24 weeks]. Safety and bio-
markers were also evaluated. All these endpoints were eval-
uated in the patients enrolled in both parts.
Safety and efficacy assessments
Safety assessment including laboratory tests were per-
formed every week during the combination treatment and 
at the discontinuation of paclitaxel if it was decided to con-
tinue longer than 6 cycles. If paclitaxel was discontinued 
at the sixth cycle, then safety assessment was conducted 
every 8 weeks until the end of treatment. LVEF assess-
ment by echocardiogram was performed at the end of even-
numbered cycles during combination treatment and every 
8 weeks while on lapatinib monotherapy. Adverse events 
(AEs) were graded according to NCI-CTCAE version 3.0. 
AE terms were coded by MedDRA Ver13.1. The protocol 
defined serious AEs as all Grade 4 laboratory abnormali-
ties, Grade 3 or 4 decrease in LVEF, ≥20 % decrease in 
LVEF relative to baseline and also below the institution’s 
lower limit of normal (if the lower limit of normal was una-
vailable, decrease to less than 50 %), Grade 3 pneumonitis, 
alanine aminotransferase (ALT) >3 × upper limit of nor-
mal (ULN), and total bilirubin >2.0 × ULN (>35 % direct; 
bilirubin fractionation required). The tolerability criteria 
were defined as the toxicities related to study treatment and 
applicable to any of the following: Grade 4 neutropenia 
sustained for ≥7 days, Grade 4 thrombocytopenia, ≥Grade 
3 or clinically significant non-hematologic toxicities (other 
than nausea), or unable to start cycle 2 within 2 weeks of 
scheduled dosing due to unresolved toxicity. Patients with-
drawn from the study without disease progression were 
assessed every 12 weeks until progression, start of post-
anticancer therapy or death. Efficacy assessment was per-
formed at baseline and at the ends of every even-numbered 
cycle until withdrawal from the study. Tumor response was 
assessed by the investigators, using images or photographic 
data, in accordance with the RECIST [18]. Biomarker anal-
ysis for HER2 status was conducted based on the results 
determined by both IHC and FISH at the central laboratory.
Pharmacokinetics evaluation
Pharmacokinetics of lapatinib and/or paclitaxel were evalu-
ated in all patients enrolled in Part 1 on days 1, 8 and 14: 
day 14 for PK of lapatinib monotherapy, day 1 for pacli-
taxel monotherapy and day 8 for combination therapy. 
Plasma samples were taken pre-dose and at 0.5, 1, 1.5, 2, 
3, 4, 6, 8, 12 and 24 h post-dose. The PK parameters cal-
culated by non-compartmental analysis were maximum 
plasma concentration (Cmax), time to Cmax (tmax) and area 
under the plasma concentration curve (AUC) from 0 to 
24 h (AUC0–24) of lapatinib as well as Cmax, tmax, half-life, 
AUC extrapolated to infinity (AUC0–inf) and AUC0–24 of 
paclitaxel.
Statistical analysis
The sample size was determined based on study fea-
sibility. This study did not assert or test any statistical 
hypotheses.
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The dose-limiting toxicity (DLT) incidences were evalu-
ated in 6 patients. The intent-to-treat (ITT) population was 
analyzed for safety and efficacy analyses. PFS and OS 
were summarized using the Kaplan–Meier method. All the 
patients who had provided ample plasma samples for the 
PK parameter evaluation were treated as the PK popula-
tion. For PK parameters, the items evaluated are shown in 
Table 5.
Version 9.1.3 Unix SAS® system (a registered trademark 




A total of 12 patients were enrolled from 9 centers between 
April 2010 and June 2011, and were treated with the study 
regimen. As of 31 January 2014 (the final data cut-off date), 
6 patients had completed the study and 6 patients were fol-
lowed up for survival.
Out of 12 patients enrolled, 8 patients had both vis-
ceral and non-visceral metastatic lesions, 2 patients had 
visceral lesions only, while the other 2 patients had non-
visceral lesions only (Table 1). The median time since 
diagnosis was 12.9 months; 4 patients had received prior 
chemotherapy, of whom one had received prior trastu-
zumab. Six patients had estrogen receptor (ER)-positive 
breast cancer as assessed by a local laboratory, of whom 
4 patients were positive for both ER and progesterone 
receptor.
Tolerability and safety
The median duration of lapatinib treatment was 50.9 weeks 
(range 4–117 weeks). Toxicities other than hematologic or 
neurologic toxicities leading to dose reduction occurred 
in 4 patients; however, DLT was not observed. The num-
bers of dose reductions observed were once (1250 mg) in 
2 patients, twice (1000 mg) in 1 patient and three times 
(750 mg) in 1 patient. The primary reasons for dose 
reduction were rash, acne, diarrhea, increased ALT and 
increased aspartate aminotransferase (AST). Dose inter-
ruptions of lapatinib were reported in 10 patients, 73 times 
in total, mainly due to hematologic or neurologic toxici-
ties. The median duration of interruption was 7 days (range 
1–21 days).
For paclitaxel, the median number of cycles was 
10 cycles (range 2–36 cycles), in which eight patients 
received more than 6 cycles. Neurologic toxicity was 
the cause of the dose reduction in one patient and of the 
dose interruptions of paclitaxel in 10 patients. All 12 
patients were withdrawn from L+P, mostly due to disease 
progression.
In Part 1, the tolerability and safety of the study treat-
ment in Japanese patients were confirmed. All patients 
experienced at least one AE regardless of the relation-
ship with the study treatments, and most of them were at 
Grades 1 or 2. The most common AEs reported were alo-
pecia, neutropenia, diarrhea, decreased hemoglobin and 
rash (Table 2). Grade 3 treatment-related AEs found in 
more than 2 patients were: neutropenia (n = 7), leukope-
nia (n = 5), diarrhea (n = 3), increased ALT (n = 3) and 
increased AST (n = 2). A Grade 4 treatment-related event, 
neutropenia, occurred in 2 patients.
Rash and diarrhea were the special interest AEs for 
lapatinib. No ≥Grade 3 or serious rash was reported. One 
Grade 2 rash event led to withdrawal from study treat-
ment in one patient who had concurrently experienced 
Grade 2 erythema of the eyelid and on the back of both 
hands. Although Grade 3 diarrhea events occurred in 3 
patients, no diarrhea was reported as ≥Grade 4 or serious, 
and there was no withdrawal from study treatment due to 
diarrhea.
Table 1  Baseline characteristics of intent-to-treat population
Based on diagnosis made by investigators
ER estrogen receptor, PgR progesterone receptor
Age, years
 Median (range) 59.0 (45–70)
Time since diagnosis (months)
 Median (min–max) 12.9 (0–115)
 1st Quartile 1.2
 3rd Quartile 76.4
Prior anti-cancer therapy, n (%)
 Chemotherapy 4 (33)
  Anthracyclines 1 (8)
    Taxanes 3 (25)
   Trastuzumab 1 (8)
 Surgery 6 (50)
 Radiotherapy 2 (17)
 Endocrine therapy 4 (33)
 Immunotherapy 0
Metastatic sites, n (%)
 Visceral 2 (17)
 Non-visceral 2 (17)
 Visceral and non-visceral 8 (67)
Hormone receptor status, n (%)
 ER+ and/or PgR+ 6 (50)
  ER+ and PgR+ 4 (33)
  ER+ and PgR− 2 (17)
 ER− and PgR− 6 (50)
 Unknown 0
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No fatal serious AE was reported. Four protocol-
defined serious AEs were reported in 3 patients; these were 
decreased neutrophil count in 2 patients, left ventricular 
dysfunction in a patient with a history of prior anthracy-
cline treatment for other past malignancy, and pneumonia 
in a patient who was diagnosed by X-ray imaging. All these 
were considered by investigators to be treatment-related. 
Although the follow-up of left ventricular dysfunction was 
discontinued due to the start of another treatment, other 
serious AEs resolved within 2 weeks.
Efficacy
As of the end of the study, 6 patients had died. The remain-
ing 6 patients were censored at the last visit. The median 
OS as primary endpoint was 35.6 months (95 % CI 
23.9, not reached; Fig. 1). PFS was analyzed using the 
results evaluated by the investigators and the median was 
13.9 months (95 % CI 7.6, 27.9; Fig. 2).
Ten out of 12 patients (83 %) achieved clinical benefit 
(95 % CI 51.6, 97.9) based on the investigators’ assessment 
(Table 3). The ORR in the ITT population was 83 % (95 % 
CI 51.6, 97.9) with 10 PRs, while one patient had SD for 
less than 24 weeks and progressive disease was observed in 
one patient.
Pharmacokinetics
The plasma concentration–time profile of lapatinib after 
repeated oral dosing of lapatinib 1500 mg with or with-
out concomitant administration of paclitaxel is shown in 
Fig. 3, and the plasma concentration–time profile of pacli-
taxel after 1 h intravenous infusion of paclitaxel 80 mg/m2 
with or without concomitant administration of lapatinib is 
shown in Fig. 4.
The geometric means of Cmax and AUC(0–24) of lapat-
inib were increased by 59 and 42 % under the paclitaxel 
80 mg/m2 combination, in comparison to lapatinib alone. 
No change was observed in tmax (Table 4). The geometric 
means of Cmax and tmax of paclitaxel were not changed by 
combination with lapatinib; however, that of AUC(0–inf) was 
increased by 23 % (Table 5).
Table 2  Summary of adverse events with at least 50 % occurrence
ALT alanine aminotransferase, AST aspartate aminotransferase
Adverse event, n (%) Grade 1 Grade 2 Grade 3 Grade 4 Total
Alopecia 6 (50) 6 (50) 0 0 12 (100)
Diarrhea 4 (33) 4 (33) 3 (25) 0 11 (92)
Neutropenia 0 2 (17) 7 (58) 2 (17) 11 (92)
Decreased  
hemoglobin
3 (25) 6 (50) 1 (8) 0 10 (83)
Rash 6 (50) 3 (25) 0 0 9 (75)
Stomatitis 8 (67) 0 0 0 8 (67)
Fatigue 8 (67) 0 0 0 8 (67)
Peripheral sensory 
neuropathy
6 (50) 2 (17) 0 0 8 (67)
Leukopenia 0 3 (25) 5 (42) 0 8 (67)
Decreased apatite 4 (33) 3 (25) 0 0 7 (58)
Paronychia 5 (42) 2 (17) 0 0 7 (58)
ALT Increased 0 4 (33) 3 (25) 0 7 (58)
AST Increased 1 (8) 3 (25) 2 (17) 0 6 (50)
Lymphopenia 1 (8) 4 (33) 1 (8) 0 6 (50)
Decreased  
hematocrit
5 (42) 1 (8) 0 0 6 (50)
Vomiting 4 (33) 2 (17) 0 0 6 (50)
Nasopharyngitis 5 (42) 1 (8) 0 0 6 (50)
Nail disorder 4 (33) 2 (17) 0 0 6 (50)
Fig. 1  Kaplan–Meier estimates for overall survival
Fig. 2  Kaplan–Meier estimates for progression-free survival 
assessed by investigators
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Discussion
The tolerability of the lapatinib (1500 mg/day) and weekly 
paclitaxel (80 mg/m2) combination was confirmed in Japa-
nese patients with HER2-positive MBC. Reported results 
from the pilot part of the Asian Phase III study targeting 
gastric cancer patients showed a similar tolerability of this 
regimen [19].
Drug–drug interaction of lapatinib and paclitaxel was 
found, as the AUC and Cmax of Japanese breast cancer 
patients given the combination were affected. A similar 
trend of interaction was observed in a Phase I study target-
ing solid tumor patients conducted outside of Japan [14]. 
The extent of drug interaction of L+P was also similar to 
those of the pilot part of the Asian Phase III study which 
included patients with a history of gastrectomy [19]. The 
interaction found in PK profiles of lapatinib and paclitaxel 
is consistent regardless of the cancer type, and such inter-
action was considered to be the result of lapatinib being a 
weak metabolism-dependent inhibitor of CYP3A4.
The AEs reported in this study were generally consistent 
with those reported in overseas clinical studies evaluating 
L+P and with known safety profiles of lapatinib and pacli-
taxel given as monotherapy [14–17]. The grade of diarrhea 
was slightly worsened compared with lapatinib monother-
apy, which means that L+P would require more careful 
management in clinical practice.
Our study demonstrated that the combination therapy of 
L+P was efficacious for the treatment of HER2-positive 
MBC, which was consistent with the results of a Phase 
III study [16]. Meanwhile, results became available from 
another global Phase III study which showed a significant 
PFS of a trastuzumab-containing regimen compared with 
a lapatinib and taxane regimen [17]. Moreover, the results 
of a trastuzumab, docetaxel and pertuzumab tri-regimen 
became available after the results of that global study 
were reported, and, up to 2014, this tri-regimen became 
the standard in first-line therapy of MBC worldwide [20]. 
As the new treatment of trastuzumab, pertuzumab and 
docetaxel tri-regimen became available for MBC and the 
results of direct comparison between lapatinib and trastu-
zumab were confirmed, it is now proven to be difficult to 
recommend L+P as the first-line therapy, which we origi-
nally expected.
Overall, our study provides valuable results that show 
the drug–drug interaction and PK interaction between 
lapatinib and paclitaxel in Japanese patients with MBC. 
Although our study does not impact upon the clinical posi-
tions or the treatment strategy, it confirms that the combi-
nation of lapatinib with paclitaxel is tolerable in Japanese 
Table 3  Summary of tumor response in intent-to-treat population
CBR clinical benefit rate (CR; PR; SD ≥24 weeks), CR complete 
response, NE not evaluable, ORR overall tumor response rate, PD 
progressive disease, PR partial response, SD stable disease
Best response, n (%)
CR 0
PR 10 (83)
SD, ≥24 weeks 0
SD, <24 weeks 1 (8)
PD 1 (8)
NE 0
ORR 83 (95 % CI 51.6, 97.9)
CBR 83 (95 % CI 51.6, 97.9)
Fig. 3  Plasma concentration–time profile of lapatinib after dosing 
of lapatinib 1500 mg with or without concomitant administration of 
paclitaxel 80 mg/m2
Fig. 4  Plasma concentration–time profile of paclitaxel after dosing 
of paclitaxel 80 mg/m2 with or without concomitant administration of 
lapatinib 1500 mg
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patients with MBC. Nevertheless, paclitaxel remains a 
key drug in breast cancer therapies and many multiple-
agent regimens with paclitaxel have been evaluated world-
wide. For this, it is considered that our findings of PK and 
safety data of L+P may be beneficial to those who seek the 
appropriate dose and safety management of the regimen. 
Currently, studies targeting the adjuvant/neoadjuvant set-
ting in which to evaluate combinations such as lapatinib, 
paclitaxel and trastuzumab are ongoing. There is no evi-
dence to recommend the use of lapatinib in comparison to 
trastuzumab; however, our data can be utilized for consid-
ering the best practice of HER2 targeting therapies.
In conclusion, L+P was tolerable in Japanese patients 
with MBC, with manageable safety profiles, and a similar 
trend of the interaction of L+P to that previously reported 
in other ethnicities, as well as in different cancer types, was 
found.
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